Singapore, 8 January 2020
Hummingbird Bioscience, an innovative biotherapeutics company pioneering
the discovery and development of new breakthrough precision antibody
therapeutics for difficult-to-treat conditions, today announced the publication
of preclinical data for its lead candidate, HMBD-001, an anti-HER3 antibody, in
Molecular Cancer Therapeutics, a
peer-reviewed American Association of Cancer Research journal.
is a unique anti-HER3 antibody with a novel mechanism of action and favorable safety profile. HER3 is a member of the EGFR tyrosine
kinase receptor family, which is responsible for driving cancer cell division
and growth, and is expressed in over half of colorectal and gastric cancers, at
least a third of breast cancers, as well as significant sub-populations of many
other indications . HER3
activation is implicated in cancer progression as well as in acquired resistance to drugs
against other tyrosine kinase receptor family members such as EGFR (e.g.
cetuximab or Erbitux) and HER2 (e.g. trastuzumab or Herceptin). HMBD-001 was developed
using Hummingbird Bioscience’s proprietary Rational Antibody Discovery Platform
to specifically bind to and inhibit a difficult-to-access region of the HER3
protein that is essential for activation.
findings show that HMBD-001 (also known as 10D1F)
is superior at tumor growth inhibition, regardless of how HER3 is activated,
compared to previous anti-HER3
drugs with different binding sites and mechanisms of action. HMBD-001 demonstrated
potent efficacy in
a broad panel of in vitro and in vivo tumor models that had high
HER3 activity and oncogenic downstream signaling.
attempts to target HER3 with other drugs failed as they could not inhibit activation
of HER3 effectively. The highly specific binding of HMBD-001 to a
difficult-to-target region on HER3 allows us to completely shut-off activation
of this important cancer-associated protein,” said Dr Jerome Boyd-Kirkup, Chief Scientific Officer
and co-founder, Hummingbird Bioscience. “This preclinical data provides
proof-of-concept and represents exciting therapeutic opportunities for us as we look
to develop HMBD-001 in hard-to-treat conditions such as gastric, colorectal,
lung and pancreatic cancers.”
Bioscience, in partnership with Cancer Research UK, will be advancing HMBD-001
into clinical trials for the treatment of HER3 driven cancers. HMBD-001 is
expected to enter Phase I trial following regulatory submission approvals in
the second half of 2020.
The paper titled 10D1F,
An Anti-HER3 Antibody that Uniquely Blocks the Receptor Dimerization Interface,
Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models” can also
be accessed online.
 Li Q., Zhang R., Yan H., Zhao P., Wu L.,
Wang H., Li T., Cao B. Prognostic significance of HER3 in patients with
malignant solid tumors. Oncotarget. 2017; 8: 67140-67151.
HMBD-001 represents a unique, highly-specific, anti-HER3 neutralizing
antibody with a novel mechanism of action that offers significant potential for
broad clinical benefit. Previous attempts to block the HER3 receptor, a key
player in the signaling pathway that promotes cell division and tumor growth in
cancer, have not proven to be efficacious. HER3 is activated by the binding of
neuregulin (NRG1), which stabilizes a transient open conformation to allow it
to form heterodimers with HER2/EGFR. In the presence of abundant HER2/EGFR,
heterodimers can form without NRG1.
Preclinical models have shown that HMBD-001 is able to effectively and uniquely
bind to a difficult-to-target region on HER3, blocking the heterodimerization of HER3
with HER2/EGFR independent of NRG1 binding. This potently inhibits the
activation of the signaling pathway – and consequently, stops tumor
Cancer Research UK has partnered with Hummingbird Bioscience to advance
this novel antibody drug into clinical trials for the treatment of HER3-driven
cancer. The clinical trial of this investigational candidate is expected to
commence following regulatory submission approvals in the second half of 2020.
About Hummingbird Bioscience
Bioscience is an innovative biotherapeutics company pioneering the discovery
and development of new breakthrough precision antibody therapies for
difficult-to-treat conditions. Leveraging its proprietary rational antibody
discovery platform and deep experience in systems biology, Hummingbird Bioscience
is able to accurately identify novel disease targets enabling it to engineer
and generate antibodies to precisely hit these difficult targets. The company is
developing a broad pipeline of first and best-in-class drug candidates across
multiple indications, including: HMBD-001, an anti-HER3 antibody, and HMBD-002,
an anti-VISTA antibody, for the treatment of cancer. Hummingbird Bioscience has
established strategic collaborations with Cancer Research UK and Amgen, and has
been awarded a product development grant from the Cancer Prevention and
Research Institute of Texas.
is located in Singapore, Houston, Texas and South San Francisco, California. To
learn more about its science, pipeline assets, and team, please visit: www.hummingbirdbioscience.com or follow the company on LinkedIn and Twitter at @Hummingbirdbio.